Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04462952
Recruitment Status : Recruiting
First Posted : July 8, 2020
Last Update Posted : July 8, 2020
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
This is a phase I, open-label study to assess the safety, tolerability, pharmacokinetics(PK) and anti-tumour activity of adavosertib in Japanese patients with advanced solid tumours. This study consists of 2 cohorts, Cohort1 and Cohort2. At least 3, or up to 6, evaluable Japanese patients with advanced solid tumours will be enrolled in each cohort to confirm the tolerability.

Condition or disease Intervention/treatment Phase
Advanced Solid Tumours Drug: Adavosertib (AZD1775) Phase 1

Detailed Description:

Objectives:

Primary objective:

To assess the safety and tolerability, describe any dose-limiting toxicity (DLT) for adavosertib

Secondary objective:

To determine the PK profile of adavosertib To describe adavosertib's preliminary anti-tumour activity using the Response Evaluation Criteria in Solid Tumours (RECIST) v1.1

Overall design:

This is a phase I, open-label study to assess the safety, tolerability, PK and anti-tumour activity of adavosertib in Japanese patients with advanced solid tumours. This study consists of 2 cohorts, Cohort1 and Cohort2. At least 3, or up to 6, evaluable Japanese patients with advanced solid tumours will be enrolled in each cohort. The total number of subjects will depend upon the available data in each cohort and the Safety Review Committee (SRC)'s decision.

Study Period:

The study is expected to start in June 2020 and end in April 2021.

Number of Subjects:

6 to 12 evaluable subjects will be enrolled in this study to confirm the tolerability.

Treatments and treatment duration:

Subjects in each part will receive the study treatments as described below:

Cohort 1: Adavosertib 250 mg by mouth (PO) once daily (QD) for 5 days ON and 2 days OFF for week 1 and 2 of a 21 days cycle Cohort 2: Adavosertib 300 mg PO QD for 5 days ON and 2 days OFF for week 1 and 2 of a 21 days cycle Subjects will be allowed to continue adavosertib until disease progression, intolerable toxicity, or discontinuation criteria have been met.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 6 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Phase I, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-Tumour Activity of Adavosertib (AZD1775) in Japanese Patients With Advanced Solid Tumours
Actual Study Start Date : June 24, 2020
Estimated Primary Completion Date : January 21, 2021
Estimated Study Completion Date : January 21, 2021

Arm Intervention/treatment
Experimental: Adavosertib monotherapy
Dose escalation of adavosertib monotherapy for patients with advanced solid tumours
Drug: Adavosertib (AZD1775)
Adavosertib taken orally




Primary Outcome Measures :
  1. Incidence of Adverse events [ Time Frame: From the informed consent to 30 days post last dose ]
    Investigate the safety and tolerability of adavosertib

  2. Incidence of Dose-limiting toxicity (DLTs) [ Time Frame: From the first dose of adavosertib up to the assessment prior to the planned first dose of Cycle 2 (each cycle is 21 days) ]
    Investigate the safety and tolerability of adavosertib


Secondary Outcome Measures :
  1. Maximum plasma drug concentration observed (Cmax) [ Time Frame: Samples will be collected on Cycle 1 Day 1,5 and Cycle 2 Day 5, Cycle 3 Day 5 and Cycle 5 Day 5 (each cycle is 21 days). ]
    PK parameters will be derived using standard, non-compartmental methods

  2. Time of maximum plasma drug concentration observed (tmax) [ Time Frame: Samples will be collected on Cycle 1 Day 1,5 and Cycle 2 Day 5, Cycle 3 Day 5 and Cycle 5 Day 5 (each cycle is 21 days). ]
    PK parameters will be derived using standard, non-compartmental methods

  3. Area under the plasma concentration-time curve from zero to 24 hours (AUC0-24) [ Time Frame: Samples will be collected on Cycle 1 Day 1,5 and Cycle 2 Day 5, Cycle 3 Day 5 and Cycle 5 Day 5 (each cycle is 21 days). ]
    PK parameters will be derived using standard, non-compartmental methods

  4. trough plasma concentration (Ctrough) [ Time Frame: Samples will be collected on Cycle 1 Day 1,5 and Cycle 2 Day 5, Cycle 3 Day 5 and Cycle 5 Day 5 (each cycle is 21 days). ]
    PK parameters will be derived using standard, non-compartmental methods

  5. Objective response rate (ORR) [ Time Frame: Assessed every 9 weeks with RECIST from the first dose of adavosertib until disease progression. Expected to be for up to 3 months. ]
    Defined as the proportion of subjects who have a best overall response of confirmed complete response (CR) or confirmed partial response (PR)

  6. Disease control rate (DCR) [ Time Frame: Assessed every 9 weeks with RECIST from the first dose of adavosertib until disease progression. Expected to be for up to 3 months. ]
    Defined as the proportion of subjects who have a best overall response of confirmed CR,confirmed PR, or stable disease (SD)

  7. Duration of response (DoR) [ Time Frame: Assessed every 9 weeks with RECIST from the first dose of adavosertib until disease progression. Expected to be for up to 3 months. ]
    Defined as the duration from the date of first documentation of response (CR or PR), which is subsequently confirmed, to the date of documented disease progression or death due to any cause in the absence of disease progression

  8. Progressionfree free survival (PFS) [ Time Frame: Assessed every 9 weeks with RECIST from the first dose of adavosertib until disease progression. Expected to be for up to 3 months. ]
    Defined as the time from the first dose of study treatment until the date of objective disease progression or death by any cause (in the absence of progression), regardless of whether the subject withdraws from the study or receives another anti-cancer therapy prior to progression



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 120 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Major Inclusion Criteria:

  • Japanese patients ≥20 years of age at the time of study entry
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0, 1
  • Adequate bone marrow reserve or organ function
  • Female patients who are not of child-bearing potential, and fertile females of childbearing potential who agree to use adequate contraceptive measures
  • Male patients should be willing to use barrier contraception
  • Predicted life expectancy ≥12 weeks
  • Histologically or cytologically documented locally advanced or metastatic solid tumour, excluding lymphoma, for which standard therapy does not exist or has proven ineffective or intolerable
  • Measurable or non-measurable disease according to RECIST v1.1

Major Exclusion Criteria:

  • Use of anti-cancer treatment drug ≤21 days or 5 half-lives (whichever is shorter) prior to the first dose of adavosertib
  • Use of an investigational drug during the past 30 days or 5 half-lives (whichever is longer) prior to the first dose of the study treatment
  • Common Terminology Criteria for Adverse Events (CTCAE) Grade >1 toxicity from prior therapy
  • Inability to swallow oral medication or any other condition that may impact adavosertib intake/absorption
  • Known malignant central nervous system (CNS) disease other than neurologically stable, treated brain metastases
  • Any of the cardiac diseases currently or within the last 6 months
  • Any underlying medical condition that would impair the patient's ability to receive study treatment
  • Other invasive malignancy within 5 years prior to the first dose of study drug except for non-invasive malignancies

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04462952


Contacts
Layout table for location contacts
Contact: AstraZeneca Clinical Study Information Center 1-877-240-9479 information.center@astrazeneca.com

Locations
Layout table for location information
Japan
Research Site Recruiting
Chuo-ku, Japan, 104-0045
Sponsors and Collaborators
AstraZeneca
Layout table for additonal information
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT04462952    
Other Study ID Numbers: D601HC00008
First Posted: July 8, 2020    Key Record Dates
Last Update Posted: July 8, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Time Frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access Criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
URL: https://astrazenecagroup-dt.pharmacm.com/DT/Home

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
MK-1775
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action